(NASDAQ: KALV) Kalvista Pharmaceuticals's forecast annual revenue growth rate of 315.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.75%.
Kalvista Pharmaceuticals's revenue in 2025 is $1,426,000.On average, 1 Wall Street analysts forecast KALV's revenue for 2025 to be $853,843,331, with the lowest KALV revenue forecast at $853,843,331, and the highest KALV revenue forecast at $853,843,331. On average, 3 Wall Street analysts forecast KALV's revenue for 2026 to be $1,834,297,986, with the lowest KALV revenue forecast at $596,174,633, and the highest KALV revenue forecast at $2,526,163,700.
In 2026, KALV is forecast to generate $6,178,996,410 in revenue, with the lowest revenue forecast at $6,178,996,410 and the highest revenue forecast at $6,178,996,410.